Clinical Trial Update: Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of two doses of an MF59-adjuvanted monovalent influenza vaccine using an H5N1 surface antigen in adults and el…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza
• Influenza Virus H5n1

Drugs mentioned

• Focetria (A/H1N1 swine-origin influenza vaccine, monovalent)

Snippet

Sponsor: Novartis Vaccines | Conditions: Prepandemic Influenza Vaccine | Phase 2 | Status: COMPLETED